ondansetron has been researched along with Adenocarcinoma Of Kidney in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron or droperidol was given intravenously, 30 min prior to the first dose of IL-2 and then every 8 h for the duration of IL-2 treatment." | 2.67 | A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. ( Cole, DJ; Kim, H; Rosenberg, SA; Steinberg, SM; Weber, JS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, H | 1 |
| Rosenberg, SA | 1 |
| Steinberg, SM | 1 |
| Cole, DJ | 1 |
| Weber, JS | 1 |
1 trial available for ondansetron and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Topics: Adult; Aged; Carcinoma, Renal Cell; Droperidol; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin | 1994 |